Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talibegron SCHEMBL6060362 | 1.00 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL328977 | 1.00 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL1230810 | 0.99 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL8976330 | 0.99 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976026 | 0.90 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976032 | 0.90 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976399 | 0.89 | ALOX15 (0.78) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976317 | 0.89 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976435 | 0.89 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976401 | 0.89 | ALOX15 (0.78) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ALOX15 888/4885ADRB3 5/4885ADRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.